The University of Chicago Header Logo

Connection

Mark J. Ratain to Medical Oncology

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Medical Oncology.
Mark J. Ratain
Connection Strength
3.998
Medical Oncology
  1. Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies. Clin Trials. 2024 Oct; 21(5):650-656.
    View in: PubMed
    Score: 0.704
  2. Oncology Drug Prescribing: The Influences of Greed and Fear. JCO Oncol Pract. 2022 09; 18(9):e1384-e1387.
    View in: PubMed
    Score: 0.622
  3. Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement. J Clin Oncol. 2019 09 10; 37(26):2368-2377.
    View in: PubMed
    Score: 0.506
  4. The impact of industry on oncology research and practice. Am Soc Clin Oncol Educ Book. 2015; 130-7.
    View in: PubMed
    Score: 0.369
  5. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010 Nov 01; 16(21):5296-302.
    View in: PubMed
    Score: 0.274
  6. Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11.
    View in: PubMed
    Score: 0.225
  7. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?". Clin Cancer Res. 2007 Nov 01; 13(21):6540.
    View in: PubMed
    Score: 0.225
  8. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res. 2007 Apr 15; 13(8):2400-5.
    View in: PubMed
    Score: 0.216
  9. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
    View in: PubMed
    Score: 0.213
  10. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.204
  11. An Expanded Role for IRBs in the Oversight of Research Biopsies. Ethics Hum Res. 2022 Sep; 44(5):32-41.
    View in: PubMed
    Score: 0.157
  12. User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20; 33(12):1414-5.
    View in: PubMed
    Score: 0.093
  13. Value-based insurance design: aligning incentives, benefits, and evidence in oncology. J Natl Compr Canc Netw. 2012 Jan; 10(1):18-23.
    View in: PubMed
    Score: 0.075
  14. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
    View in: PubMed
    Score: 0.039
  15. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
    View in: PubMed
    Score: 0.036
  16. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol. 1992 Nov; 10(11):1810-6.
    View in: PubMed
    Score: 0.020
  17. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
    View in: PubMed
    Score: 0.014
  18. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.